Adenosine infusion for the management of persistent pulmonary hypertension of the newborn

Pediatr Crit Care Med. 2004 Jan;5(1):10-3. doi: 10.1097/01.CCM.0000105309.27519.27.

Abstract

Objective: To determine the effect of adenosine for the management of persistent pulmonary hypertension of the newborn.

Design: Prospective, observational case series report.

Setting: A single, tertiary referral neonatal intensive care unit.

Patients: Nine neonates with persistent pulmonary hypertension of the newborn requiring mechanical ventilation and inhaled nitric oxide at 20 parts per million.

Interventions: A continuous intravenous infusion of adenosine at 50 microg/kg/min.

Measurements and main results: Peripheral arterial oxygen saturation, arterial oxygen tension, invasive systemic arterial blood pressure, and pulmonary arterial pressure, estimated using echocardiography, were recorded. There was a significant improvement in arterial oxygenation tension in six of nine neonates who responded to adenosine: PaO2 increased from 66.8 (range, 47-70.5) torr (8.8 kPa) to 73.5 (range, 58.5-94.2) (p=.02) and pulmonary arterial pressure decreased significantly from 63 (range, 42.5-64.0) to 43.5 (range, 32.75-49) mm Hg (p=.002). The pulmonary to systemic mean artery pressure ratio fell from 1.27 (range, 0.88-1.5) to 0.81 (range, 0.64-0.84) (p=.002). Three neonates did not respond to adenosine infusion.

Conclusions: The use of adenosine infusion in combination with inhaled nitric oxide may be a potentially valuable therapeutic option for the treatment of pulmonary hypertension of the newborn. Neonates with irreversible lung pathology may not respond to adenosine infusion.

Publication types

  • Clinical Trial

MeSH terms

  • Adenosine / therapeutic use*
  • Administration, Inhalation
  • Drug Therapy, Combination
  • Humans
  • Infant, Newborn
  • Infusions, Intravenous
  • Nitric Oxide / therapeutic use
  • Persistent Fetal Circulation Syndrome / drug therapy*
  • Prospective Studies
  • Vasodilator Agents / therapeutic use*

Substances

  • Vasodilator Agents
  • Nitric Oxide
  • Adenosine